Daiichi Sankyo signs agreement with Translational Sciences, Inc. to develop and commercialize the first-in-class thrombus dissolving agent, TS23

Daiichi SankyoDaiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) has signed an exclusive licensing agreement with Translational Sciences, Inc. to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23, which is currently undergoing Phase I clinical trials.

Based on this agreement, Daiichi Sankyo will pay Translational Sciences unspecified fees, milestones and royalties for exclusive rights to globally develop and commercialize TS23.

This agreement with Translational Sciences, Inc. for Daiichi Sankyo to develop and commercialize this unique thrombus dissolving agent, TS23, is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis.

Dr. Guy Reed, CSO/CEO of Translational Sciences said: "Daiichi Sankyo recognized the great potential of this novel therapy. We believe they have the expertise and resources to fully develop it for the millions of patients each year who suffer cardiovascular disease and stroke. We are enormously grateful to the National Institutes of Health who provided crucial support to translate this research into therapy."

About Translational Sciences
Translational Sciences, Inc. (Memphis, TN, USA) is a clinical stage, biopharmaceutical company that develops first-in-class therapeutics for the safe and effective treatment of acute cardiovascular diseases and ischemic stroke. Development of TS23 was supported by the National Institutes of Health, specifically the National Heart, Lung, And Blood Institute (Award R44HL092750) and the National Institute Of Neurological Disorders And Stroke (Award U44NS073147).

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group's research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...